Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Solicits Input On Coverage Of Ambulatory Blood Pressure Monitoring

Executive Summary

The agency is reopening the coverage policy on ambulatory blood pressure monitoring, non-invasive blood pressure measurement over 24-hour cycles, in response to a request from medical professional societies. Currently, Medicare only covers ABPM in limited circumstances where there is reason to believe a patient's in-office blood-pressure is not an accurate representation of their normal blood pressure.

You may also be interested in...



White Coat, Masked Hypertensives Could Win Ambulatory Blood Pressure Monitoring Coverage Under CMS Proposal

An April 9 proposed decision memo from the US Centers for Medicare and Medicaid Services would allow additional coverage for use of ambulatory blood pressure monitoring (APBM) devices by Medicare beneficiaries with known or suspected high blood pressure who meet specific criteria defined by the agency.

Medicare makes ambulatory BP (blood pressure) coverage decision

Medicare will soon begin covering ambulatory blood pressure monitoring to determine whether a patient's blood pressure is high due to fears about being in a doctor's office, or is high for any other reason that requires management.

TCT 2022: Trial Of Boston Scientific’s TAVR Embolic Protector Misses Endpoint, But May Offer 'Hope'

New trial data shows Boston Scientific’s Sentinel cerebral embolic protection device may reduce the risk of disabling stroke, but it does not appear to reduce the overall risk of stroke.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT123410

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel